UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO) exercised 9,500 stock options and sold 9,500 United Therapeutics Corp (UTHR) common shares via a 10b5-1 plan on August 19, 2026, for roughly $5 million in proceeds.

On August 19, 2026, United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share and acquired an equivalent 9,500 shares of common stock, then sold 9,500 shares of common stock in a series of open-market transactions at weighted-average prices ranging from approximately $522.49 to $535.22 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The gross value of the option exercise was about $1.29 million (based on the exercise price), while the gross proceeds from the sales were approximately $4.99 million, leaving the reporting person with 324,443 shares held indirectly by trust, along with additional direct, spousal, and trust holdings disclosed in the filing. The plan is part of a broader program to exercise up to 1,734,410 options expiring March 15, 2027, or until December 31, 2026, whichever comes first, suggesting a pre-scheduled diversification strategy rather than an opportunistic trade.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000124

Alert Tier

7